---
schema_version: "secwatch.filing_event.v1"
accession: "0001703057-25-000018"
form_type: "8-K"
ticker: "ABCL"
cik: "0001703057"
company_name: "AbCellera Biologics Inc."
filed_at: "2025-09-10T23:59:59+00:00"
generated_at: "2026-05-17T07:02:23.990984+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# AbCellera appoints Sarah Noonberg as first Chief Medical Officer

## Summary
- Dr. Sarah Noonberg appointed CMO effective September 10, 2025; she is AbCellera's first CMO.
- Noonberg brings over 20 years experience, previously CMO at Metagenomi and other biotechs.
- She will lead clinical development of AbCellera's antibody-based therapeutic pipeline.
- Appointment marks company transition from discovery to clinical-stage organization.

## SEC filing metadata
- accession: 0001703057-25-000018
- form_type: 8-K
- ticker: ABCL
- cik: 0001703057
- company_name: AbCellera Biologics Inc.
- filed_at: 2025-09-10T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1703057/000170305725000018/0001703057-25-000018-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1703057/000170305725000018/abcl-20250910.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001703057-25-000018
- JSON: https://secwatch.observer/filing/0001703057-25-000018.json
- Plain text: https://secwatch.observer/filing/0001703057-25-000018.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.